£700,000 MRC ‘Confidence in Concept’ award to accelerate the most promising drug discovery projects
2 August 2012
UCL has been awarded £700,000 by the Medical Research Council (MRC) and the Technology Strategy Board under the joint £180 million Biomedical Catalyst.
The first awards were announced today by Minister for Universities and Science David Willetts at the British Business Embassy’s life sciences summit at Lancaster House.
These initial awards, which will inject nearly £10m into 14 universities and 18 small and medium-sized enterprises (SMEs), will support UK academics and businesses on the vital first step in exploring the market potential of their early-stage scientific ideas.The MRC ‘Confidence in Concept’ awards, totalling £7.4m, will give universities grants of between £360,000 and £750,000 to help them progress more promising research ideas towards clinical testing.
Dr David D Miller (Director, Translational Research and Industrial Partnerships) led the successful UCL application. The award will provide a devolved fund that will be allocated internally to a variety of emerging projects in order to help them reach the stage of maturity where they will have a good chance of attracting major translational funding.
Minister for Universities and Science David Willetts said:
“The UK’s world leading life sciences industry is changing fast and we need to stay ahead of the game. The Biomedical Catalyst will help bridge the so-called ‘valley of death’ that exists between when a bright new idea is developed in the laboratory and the point when a new drug or technology can be invested in by the market. This will support our most innovative life sciences SMEs and academics, drive growth and benefit patients.”
Dr Wendy Ewart, Deputy Chief Executive of the MRC, said:
“The MRC’s Confidence in Concept awards will empower leading UK universities to respond quickly to emerging translational opportunities as they arise. They will give academic researchers the opportunity to generate enough evidence to leverage further investment from a variety of sources to progress the best ideas, helping to bridge the gap between discovery and development.”
David Bott, Director of Innovation Programmes at the Technology Strategy Board, said:
“We are delighted to make these first funding awards through the Biomedical Catalyst, which will help bridge the funding gap between the development of a new idea and investment by the market in a new drug or technology, and provide effective support for the best life science opportunities arising in the UK.”
The Biomedical Catalyst, announced by Prime Minister David Cameron in December 2011, is a programme of public funding designed to deliver growth to the UK life sciences sector. Delivered jointly by the MRC and the Technology Strategy Board, the Catalyst is a key feature of the UK Government’s Life Sciences Strategy.
The first applications for larger translational projects through the Biomedical Catalyst, including those seeking to demonstrate clinical utility, are currently under consideration. Funding for successful applications will be announced before the end of October this year.